GlassScriptPhysician profile
Stephen H Bush
NPI 1013980416
$33,463.51
in general payments reported to CMS, 2019-2025
32 companies · $5,176 in 2025
The $5,176 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,981 · 2020: $1,906 · 2021: $13K · 2022: $4,252 · 2023: $3,793 · 2024: $3,688 · 2025: $5,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Education: $4,379 · Food and Beverage: $1,311 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Education | $4,379.19 |
| Food and Beverage | $1,310.84 |
| Travel and Lodging | $967.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $24,187.18 | 2019-2024 | Gelpoint V-Path |
| Intuitive Surgical, INC. | $4,523.21 | 2019-2025 | Da Vinci Surgical System |
| Ethicon US, LLC | $1,730.31 | 2019-2025 | Stratafix, Ethicon, Vistaseal |
| Glaxosmithkline, LLC. | $605.98 | 2020-2022 | |
| Pfizer INC. | $303.08 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $283.91 | 2021 | |
| Abbvie INC. | $266.99 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $203.03 | 2025 | Myfembree, Gemtesa |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Eisai INC. | $129.84 | 2019-2023 | |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2025 | Exparel |
| Astrazeneca Pharmaceuticals LP | $119.79 | 2021 | |
| Amag Pharmaceuticals, INC. | $118.68 | 2019-2020 | |
| Lupin INC. | $91.55 | 2019 | |
| Therapeuticsmd, INC. | $88.09 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $75.10 | 2019-2024 | Veozah |
| Immunogen, INC. | $70.99 | 2023 | Elahere |
| Boston Scientific Corporation | $64.73 | 2019-2022 | |
| Sage Therapeutics, LLC | $57.85 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $31.15 | 2020-2021 | |
| Coopersurgical, INC. | $26.51 | 2022 | |
| Conmed Corporation | $24.41 | 2022 | |
| Fennec Pharmaceuticals, INC. | $20.74 | 2025 | Fyarro |
| Baxter Healthcare | $18.83 | 2024 | Perclot |
| Mallinckrodt Enterprises LLC | $16.68 | 2019 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Medtronic, INC. | $15.92 | 2025 | Ligasure |
| Acessa Health INC. | $14.37 | 2019 | |
| Avion Pharmaceuticals | $14.02 | 2019 | |
| Allergan, INC. | $13.34 | 2019 | |
| Meditrina | $11.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.